Amy Lehman
Amy Lehman
Principal Biostatistician, Exact Sciences
Verified email at - Homepage
Cited by
Cited by
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, ...
Blood, The Journal of the American Society of Hematology 122 (15), 2539-2549, 2013
BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia
JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ...
Journal of Clinical Oncology 35 (13), 1437, 2017
Ibrutinib treatment improves T cell number and function in CLL patients
M Long, K Beckwith, P Do, BL Mundy, A Gordon, AM Lehman, ...
The Journal of clinical investigation 127 (8), 3052-3064, 2017
Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation
AD Buhimschi, HA Armstrong, M Toure, S Jaime-Figueroa, TL Chen, ...
Biochemistry 57 (26), 3564-3575, 2018
Chronic stress and susceptibility to skin cancer
AN Saul, TM Oberyszyn, C Daugherty, D Kusewitt, S Jones, S Jewell, ...
Journal of the National Cancer Institute 97 (23), 1760-1767, 2005
Techniques for handling missing data in secondary analyses of large surveys
DL Langkamp, A Lehman, S Lemeshow
Academic pediatrics 10 (3), 205-210, 2010
Combination therapy with anti–CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity
E Kocak, K Lute, X Chang, KF May Jr, KR Exten, H Zhang, ...
Cancer research 66 (14), 7276-7284, 2006
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
DM Lucas, RB Edwards, G Lozanski, DA West, JD Shin, MA Vargo, ...
Blood, The Journal of the American Society of Hematology 113 (19), 4656-4666, 2009
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
JA Dubovsky, R Flynn, J Du, BK Harrington, Y Zhong, B Kaffenberger, ...
The Journal of clinical investigation 124 (11), 4867-4876, 2014
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
X Zhao, R Lapalombella, T Joshi, C Cheney, A Gowda, ...
Blood, The Journal of the American Society of Hematology 110 (7), 2569-2577, 2007
Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation
TM Liu, JA Woyach, Y Zhong, A Lozanski, G Lozanski, S Dong, E Strattan, ...
Blood, The Journal of the American Society of Hematology 126 (1), 61-68, 2015
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma
Q Liu, X Zhao, F Frissora, Y Ma, R Santhanam, D Jarjoura, A Lehman, ...
Blood, The Journal of the American Society of Hematology 111 (1), 275-284, 2008
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor–positive tumor cells is enhanced by cytokines
JM Roda, T Joshi, JP Butchar, JW McAlees, A Lehman, S Tridandapani, ...
Clinical Cancer Research 13 (21), 6419-6428, 2007
Epidemiology and risk factors for thromboembolic complications of childhood nephrotic syndrome: a Midwest Pediatric Nephrology Consortium (MWPNC) study
BA Kerlin, NB Blatt, B Fuh, S Zhao, A Lehman, C Blanchong, JD Mahan, ...
The Journal of pediatrics 155 (1), 105-110. e1, 2009
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
LA Andritsos, AJ Johnson, G Lozanski, W Blum, C Kefauver, F Awan, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression
CC Huang, A Lehman, A Albawardi, A Satoskar, S Brodsky, G Nadasdy, ...
Modern Pathology 26 (6), 799-805, 2013
Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling
YY Yeh, HG Ozer, AM Lehman, K Maddocks, L Yu, AJ Johnson, JC Byrd
Blood, The Journal of the American Society of Hematology 125 (21), 3297-3305, 2015
Interleukin-21 enhances NK cell activation in response to antibody-coated targets
JM Roda, R Parihar, A Lehman, A Mani, S Tridandapani, WE Carson
The Journal of Immunology 177 (1), 120-129, 2006
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma
KA Varker, JE Biber, C Kefauver, R Jensen, A Lehman, D Young, H Wu, ...
Annals of surgical oncology 14, 2367-2376, 2007
CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody
FT Awan, R Lapalombella, R Trotta, JP Butchar, B Yu, DM Benson Jr, ...
Blood, The Journal of the American Society of Hematology 115 (6), 1204-1213, 2010
The system can't perform the operation now. Try again later.
Articles 1–20